世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

低分子CDMO市場規模、シェア、動向分析レポート:医薬品タイプ別(ジェネリック、革新的医薬品)、製品別(原薬、完成品)、用途別(がん、CVD、中枢神経疾患)、地域別、セグメント別予測、2024年~2030年


Small Molecule CDMO Market Size, Share & Trends Analysis Report By Drug Type (Generics, Innovators), By Product (APIs, Finished Drug Products), By Application (Oncology, CVD, CNS Conditions), By Region, And Segment Forecasts, 2024 - 2030

低分子CDMO市場の成長と動向 Grand View Research, Inc.の新しい調査によると、低分子CDMOの世界市場規模は、2024年から2030年にかけて7.1%のCAGRを記録し、2030年までに1084億6000万米ドルに達すると予測され... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Grand View Research
グランドビューリサーチ
2023年12月11日 US$5,950
シングルユーザライセンス(印刷不可)
ライセンス・価格情報
注文方法はこちら
180 英語

本レポートは受注生産のため、ご納品のお時間をいただく場合がございます。


 

サマリー

低分子CDMO市場の成長と動向

Grand View Research, Inc.の新しい調査によると、低分子CDMOの世界市場規模は、2024年から2030年にかけて7.1%のCAGRを記録し、2030年までに1084億6000万米ドルに達すると予測されている。低分子医薬品開発における革新的技術の探求、低分子治療薬に焦点を当てた医薬品パイプラインの拡大、費用対効果が高く専門的な製造サービスを提供する開発・製造受託機関(CDMO)への依存の高まり、効率的な医薬品開発・製造プロセスを支援する規制の枠組み、業界の需要に応えるために製造能力を拡大するCDMOなどは、市場成長を支える要因の一部である。製薬企業にとって、技術革新と診療所への容易なアクセスは重要な要素である。

小規模企業や特殊製薬企業は、業界内でこれらの重要な要件を提供することにますます依存するようになっている。CDMOの多くは、ワンストップ・ショップ企業としての地位を確立している。ワン・ストップ・ショップ・サービス・モデルとは、CDMOが原薬(API)から剤形、初期開発から商業化まですべてを提供するものである。このようなサービスを提供するためには、CDMOは特定の問題記述に対応するための幅広い実現技術や専門的な処理能力を有していなければならない。研究、開発、製造の全サービスを提供するCDMOが世界中に相当数存在することが、市場の成長を支えていると予想される。慢性疾患の高い流行も、新規の低分子ベースの治療薬の開発を支える大きな要因であり、CDMOサービスの需要を押し上げている。

国際糖尿病連合(IDF)は、糖尿病の罹患率が国内で徐々に上昇していると述べている。それによると、2022年には中国で1億4,000万人以上が糖尿病に罹患し、2030年には1億7,440万人が糖尿病と診断される見込みである。不健康な脂肪の大量消費と座りっぱなしのライフスタイルが、糖尿病発症率を高めている主な要因である。糖尿病の負担の増大は、同国におけるCDMOサービスの需要を促進すると予想される。医薬品研究開発への多額の投資は、業界の成長を後押しする重要な原動力である。製薬会社が低分子治療薬の発見・開発に力を入れるにつれ、CDMOサービスに対する需要も増加している。これらのサービスは、低分子医薬品の効率的かつ費用対効果の高い開発・製造に不可欠である。

低分子CDMO市場レポートハイライト

- 新薬開発のための研究開発イニシアチブの増加により、2023年にはAPIセグメントが62.3%の最大シェアを占める。大手製薬企業の強固な医薬品パイプラインも同分野の成長を促進

- ジェネリック医薬品セグメントは、2024年から2030年までのCAGRが8.0%と最も高くなると予測される。がん、糖尿病、心血管疾患(CVDs)などの疾病負担の高さ、ジェネリック医薬品へのアクセスを改善するための各国政府の取り組みが、セグメント成長の主な要因である。

- がん領域は、世界的ながん患者数の増加により、2023年には35.1%と最も高い売上シェアを占めた。さらに、政府による償還政策の強化や、低分子のがん治療薬開発への資金調達の増加が、同分野の成長を後押しすると予想される。

- アジア太平洋地域は、2024年から2030年までのCAGRが7.7%と最も高くなると予想されている。北米や欧州に比べて製造コストが格段に安く、法律も整備されているため、アジア太平洋地域、特に中国とインドが圧倒的な地域市場を維持している。

ページTOPに戻る


目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. Drug Type
1.1.3. Application
1.1.4. Regional scope
1.1.5. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.3.5.1. Data for primary interviews in North America
1.3.5.2. Data for primary interviews in Europe
1.3.5.3. Data for primary interviews in Asia Pacific
1.3.5.4. Data for primary interviews in Latin America
1.3.5.5. Data for Primary interviews in MEA
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.2. Parent Market Analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Drug Type outlook
2.2.3. Application outlook
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Small Molecule CDMO Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rise in drug development pipelines
3.2.1.2. Growing reliance on CDMOS for cost-effective and specialized manufacturing services.
3.2.1.3. Capacity expansions by CDMOS
3.2.1.4. Technological advancements
3.2.2. Market restraint analysis
3.2.2.1. Growing demand for biologics
3.2.2.2. Complexity and challenges in synthesis of certain small molecules, impacting manufacturing efficiency
3.3. Small Molecule CDMO Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Small Molecule CDMO Market: Product Estimates & Trend Analysis
4.1. Definitions and Scope
4.1.1. Active Pharmaceutical Ingredients (API)
4.1.2. Finished Drug Products
4.2. Product Market Share, 2023 & 2030
4.3. Segment Dashboard
4.4. Global Small Molecule CDMO Market by Product Outlook
4.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5.1. Active Pharmaceutical Ingredients (APIs)
4.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.2. Finished Drug Products
4.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 5. Small Molecule CDMO Market: Drug Type Estimates & Trend Analysis
5.1. Definitions and Scope
5.1.1. Innovators
5.1.2. Generics
5.2. Drug Type Market Share, 2023 & 2030
5.3. Segment Dashboard
5.4. Global Small Molecule CDMO Market by Drug Type Outlook
5.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5.1. Innovators
5.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.5.2. Generics
5.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 6. Small Molecule CDMO Market: Application Estimates & Trend Analysis
6.1. Definitions and Scope
6.1.1. Oncology
6.1.2. Cardiovascular Disease
6.1.3. Central Nervous System (CNS) Conditions
6.1.4. Autoimmune/Inflammation
6.1.5. Others
6.2. Application Market Share, 2023 & 2030
6.3. Segment Dashboard
6.4. Global Small Molecule CDMO Market by Application Outlook
6.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.5.1. Oncology
6.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.2. Cardiovascular Disease
6.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.3. Central Nervous System (CNS) Conditions
6.5.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.4. Autoimmune/Inflammation
6.5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.5. Others
6.5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 7. Small Molecule CDMO Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2023 & 2030
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. North America
7.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Regulatory Framework
7.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Regulatory Framework
7.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
7.5. Europe
7.5.1. UK
7.5.1.1. Key Country Dynamics
7.5.1.2. Competitive Scenario
7.5.1.3. Regulatory Framework
7.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
7.5.2. Germany
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Regulatory Framework
7.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
7.5.3. France
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Regulatory Framework
7.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
7.5.4. Italy
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. Regulatory Framework
7.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
7.5.5. Spain
7.5.5.1. Key Country Dynamics
7.5.5.2. Competitive Scenario
7.5.5.3. Regulatory Framework
7.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
7.5.6. Denmark
7.5.6.1. Key Country Dynamics
7.5.6.2. Competitive Scenario
7.5.6.3. Regulatory Framework
7.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
7.5.7. Sweden
7.5.7.1. Key Country Dynamics
7.5.7.2. Competitive Scenario
7.5.7.3. Regulatory Framework
7.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
7.5.8. Norway
7.5.8.1. Key Country Dynamics
7.5.8.2. Competitive Scenario
7.5.8.3. Regulatory Framework
7.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
7.6. Asia Pacific
7.6.1. Japan
7.6.1.1. Key Country Dynamics
7.6.1.2. Competitive Scenario
7.6.1.3. Regulatory Framework
7.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
7.6.2. India
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Regulatory Framework
7.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Regulatory Framework
7.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
7.6.4. South Korea
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Regulatory Framework
7.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
7.6.5. Australia
7.6.5.1. Key Country Dynamics
7.6.5.2. Competitive Scenario
7.6.5.3. Regulatory Framework
7.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
7.6.6. Thailand
7.6.6.1. Key Country Dynamics
7.6.6.2. Competitive Scenario
7.6.6.3. Regulatory Framework
7.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
7.7. Latin America
7.7.1. Brazil
7.7.1.1. Key Country Dynamics
7.7.1.2. Competitive Scenario
7.7.1.3. Regulatory Framework
7.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
7.7.2. Mexico
7.7.2.1. Key Country Dynamics
7.7.2.2. Competitive Scenario
7.7.2.3. Regulatory Framework
7.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Competitive Scenario
7.7.3.3. Regulatory Framework
7.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
7.8. MEA
7.8.1. South Africa
7.8.1.1. Key Country Dynamics
7.8.1.2. Competitive Scenario
7.8.1.3. Regulatory Framework
7.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
7.8.2. Saudi Arabia
7.8.2.1. Key Country Dynamics
7.8.2.2. Competitive Scenario
7.8.2.3. Regulatory Framework
7.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
7.8.3. UAE
7.8.3.1. Key Country Dynamics
7.8.3.2. Competitive Scenario
7.8.3.3. Regulatory Framework
7.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
7.8.4. Kuwait
7.8.4.1. Key Country Dynamics
7.8.4.2. Competitive Scenario
7.8.4.3. Regulatory Framework
7.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030
Chapter 8. Competitive Landscape
8.1. Market Participant Categorization
8.1.1. Innovators
8.1.2. Market Leaders
8.1.3. Emerging Players
8.1.4. Company Market Share Analysis, 2023
8.2. Company Profiles
8.2.1. Lonza
8.2.1.1. Company overview
8.2.1.2. Financial performance
8.2.1.3. Service benchmarking
8.2.1.4. Strategic initiatives
8.2.2. Catalent, Inc
8.2.2.1. Company overview
8.2.2.2. Financial performance
8.2.2.3. Service benchmarking
8.2.2.4. Strategic initiatives
8.2.3. Thermo Fisher Scientific Inc.
8.2.3.1. Company overview
8.2.3.2. Financial performance
8.2.3.3. Service benchmarking
8.2.3.4. Strategic initiatives
8.2.4. Cambrex Corporation
8.2.4.1. Company overview
8.2.4.2. Financial performance
8.2.4.3. Service benchmarking
8.2.4.4. Strategic initiatives
8.2.5. Bellen Chemistry
8.2.5.1. Company overview
8.2.5.2. Financial performance
8.2.5.3. Service benchmarking
8.2.5.4. Strategic initiatives
8.2.6. Siegfried Holding AG
8.2.6.1. Company overview
8.2.6.2. Financial performance
8.2.6.3. Service benchmarking
8.2.6.4. Strategic initiatives
8.2.7. Recipharm AB
8.2.7.1. Company overview
8.2.7.2. Financial performance
8.2.7.3. Service benchmarking
8.2.7.4. Strategic initiatives
8.2.8. Eurofins Scientific
8.2.8.1. Company overview
8.2.8.2. Financial performance
8.2.8.3. Service benchmarking
8.2.8.4. Strategic initiatives
8.2.9. Aurigene Pharmaceutical Services Ltd.
8.2.9.1. Company overview
8.2.9.2. Financial performance
8.2.9.3. Service benchmarking
8.2.9.4. Strategic initiatives
8.2.10. CordenPharma International
8.2.10.1. Company overview
8.2.10.2. Financial performance
8.2.10.3. Service benchmarking
8.2.10.4. Strategic initiatives





 

ページTOPに戻る


 

Summary

Small Molecule CDMO Market Growth & Trends

The global small molecule CDMO market size is expected to reach USD 108.46 billion by 2030, registering a CAGR of 7.1% from 2024 to 2030, according to a new study by Grand View Research, Inc. Exploration of innovative technologies in small molecule drug development, expansion of pharmaceutical pipelines with a focus on small molecule therapeutics, growing reliance on contract development and manufacturing organizations (CDMOs) for cost-effective and specialized manufacturing services, regulatory frameworks supporting efficient drug development & manufacturing processes, and CDMOs expanding manufacturing capacities to meet industry demands are few of the factors supporting market growth. For pharmaceutical companies, innovation and easy access to clinics are critical factors.

Small-scale companies and specialty pharmaceutical players increasingly rely on delivering these important requirements within the industry. Many CDMOs establish themselves as one-stop-shop companies. The one-stop-shop service model is where a CDMO offers everything, from active pharmaceutical ingredient (API) to dosage form and early development to commercialization. To provide these services, a CDMO must have a wide range of enabling technologies and specialized handling capabilities that help address specific problem statements. A significant number of CDMOs across the globe providing all research, development, and manufacturing services is expected to support market growth. The high prevalence of chronic ailments is another considerable factor supporting the development of novel small molecule-based therapeutics, thus boosting CDMO services demand.

The International Diabetes Federation (IDF) states that the incidence of diabetes is rising gradually in the country. It states that in 2022, over 140 million people in China had diabetes, and 174.4 million are expected to be diagnosed by 2030. High consumption of unhealthy fats and a sedentary lifestyle are major factors contributing to the high incidence of diabetes. The growing burden of diabetes is expected to drive CDMO services demand in the country. Substantial investment in pharmaceutical R&D is a significant driver bolstering industry growth. As pharmaceutical companies intensify their efforts in discovering & developing small molecule therapeutics, there is a corresponding rise in demand for CDMO services. These services are crucial in the efficient & cost-effective development & manufacturing of small-molecule drugs.

Small Molecule CDMO Market Report Highlights

• The API segment accounted for the largest share of 62.3% in 2023 due to increased R&D initiatives for novel medicine development. The robust drug pipelines of major pharmaceutical players also propel segment growth

• The generics drug type segment is anticipated to have the highest CAGR of 8.0% from 2024 to 2030. The high burden of diseases, such as cancer, diabetes, and cardiovascular disorders (CVDs), and initiatives by the governments to improve access to generic drugs are the key factors contributing to segment growth

• The oncology segment held the highest revenue share of 35.1% in 2023 owing to an increasing number of cancer cases globally. Furthermore, increased government reimbursement policies and a rise in financing for developing small molecule oncology therapies are expected to boost segment growth

• Asia Pacific is anticipated to witness the highest CAGR of 7.7% from 2024 to 2030. Due to significantly cheaper manufacturing costs than North America & Europe and favorable laws, Asia Pacific, particularly China & India, has remained the dominant regional market



ページTOPに戻る


Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. Drug Type
1.1.3. Application
1.1.4. Regional scope
1.1.5. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.3.5.1. Data for primary interviews in North America
1.3.5.2. Data for primary interviews in Europe
1.3.5.3. Data for primary interviews in Asia Pacific
1.3.5.4. Data for primary interviews in Latin America
1.3.5.5. Data for Primary interviews in MEA
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.2. Parent Market Analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Drug Type outlook
2.2.3. Application outlook
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Small Molecule CDMO Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rise in drug development pipelines
3.2.1.2. Growing reliance on CDMOS for cost-effective and specialized manufacturing services.
3.2.1.3. Capacity expansions by CDMOS
3.2.1.4. Technological advancements
3.2.2. Market restraint analysis
3.2.2.1. Growing demand for biologics
3.2.2.2. Complexity and challenges in synthesis of certain small molecules, impacting manufacturing efficiency
3.3. Small Molecule CDMO Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Small Molecule CDMO Market: Product Estimates & Trend Analysis
4.1. Definitions and Scope
4.1.1. Active Pharmaceutical Ingredients (API)
4.1.2. Finished Drug Products
4.2. Product Market Share, 2023 & 2030
4.3. Segment Dashboard
4.4. Global Small Molecule CDMO Market by Product Outlook
4.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5.1. Active Pharmaceutical Ingredients (APIs)
4.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.2. Finished Drug Products
4.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 5. Small Molecule CDMO Market: Drug Type Estimates & Trend Analysis
5.1. Definitions and Scope
5.1.1. Innovators
5.1.2. Generics
5.2. Drug Type Market Share, 2023 & 2030
5.3. Segment Dashboard
5.4. Global Small Molecule CDMO Market by Drug Type Outlook
5.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5.1. Innovators
5.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.5.2. Generics
5.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 6. Small Molecule CDMO Market: Application Estimates & Trend Analysis
6.1. Definitions and Scope
6.1.1. Oncology
6.1.2. Cardiovascular Disease
6.1.3. Central Nervous System (CNS) Conditions
6.1.4. Autoimmune/Inflammation
6.1.5. Others
6.2. Application Market Share, 2023 & 2030
6.3. Segment Dashboard
6.4. Global Small Molecule CDMO Market by Application Outlook
6.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.5.1. Oncology
6.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.2. Cardiovascular Disease
6.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.3. Central Nervous System (CNS) Conditions
6.5.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.4. Autoimmune/Inflammation
6.5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.5. Others
6.5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 7. Small Molecule CDMO Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2023 & 2030
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. North America
7.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Regulatory Framework
7.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Regulatory Framework
7.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
7.5. Europe
7.5.1. UK
7.5.1.1. Key Country Dynamics
7.5.1.2. Competitive Scenario
7.5.1.3. Regulatory Framework
7.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
7.5.2. Germany
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Regulatory Framework
7.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
7.5.3. France
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Regulatory Framework
7.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
7.5.4. Italy
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. Regulatory Framework
7.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
7.5.5. Spain
7.5.5.1. Key Country Dynamics
7.5.5.2. Competitive Scenario
7.5.5.3. Regulatory Framework
7.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
7.5.6. Denmark
7.5.6.1. Key Country Dynamics
7.5.6.2. Competitive Scenario
7.5.6.3. Regulatory Framework
7.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
7.5.7. Sweden
7.5.7.1. Key Country Dynamics
7.5.7.2. Competitive Scenario
7.5.7.3. Regulatory Framework
7.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
7.5.8. Norway
7.5.8.1. Key Country Dynamics
7.5.8.2. Competitive Scenario
7.5.8.3. Regulatory Framework
7.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
7.6. Asia Pacific
7.6.1. Japan
7.6.1.1. Key Country Dynamics
7.6.1.2. Competitive Scenario
7.6.1.3. Regulatory Framework
7.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
7.6.2. India
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Regulatory Framework
7.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Regulatory Framework
7.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
7.6.4. South Korea
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Regulatory Framework
7.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
7.6.5. Australia
7.6.5.1. Key Country Dynamics
7.6.5.2. Competitive Scenario
7.6.5.3. Regulatory Framework
7.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
7.6.6. Thailand
7.6.6.1. Key Country Dynamics
7.6.6.2. Competitive Scenario
7.6.6.3. Regulatory Framework
7.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
7.7. Latin America
7.7.1. Brazil
7.7.1.1. Key Country Dynamics
7.7.1.2. Competitive Scenario
7.7.1.3. Regulatory Framework
7.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
7.7.2. Mexico
7.7.2.1. Key Country Dynamics
7.7.2.2. Competitive Scenario
7.7.2.3. Regulatory Framework
7.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Competitive Scenario
7.7.3.3. Regulatory Framework
7.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
7.8. MEA
7.8.1. South Africa
7.8.1.1. Key Country Dynamics
7.8.1.2. Competitive Scenario
7.8.1.3. Regulatory Framework
7.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
7.8.2. Saudi Arabia
7.8.2.1. Key Country Dynamics
7.8.2.2. Competitive Scenario
7.8.2.3. Regulatory Framework
7.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
7.8.3. UAE
7.8.3.1. Key Country Dynamics
7.8.3.2. Competitive Scenario
7.8.3.3. Regulatory Framework
7.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
7.8.4. Kuwait
7.8.4.1. Key Country Dynamics
7.8.4.2. Competitive Scenario
7.8.4.3. Regulatory Framework
7.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030
Chapter 8. Competitive Landscape
8.1. Market Participant Categorization
8.1.1. Innovators
8.1.2. Market Leaders
8.1.3. Emerging Players
8.1.4. Company Market Share Analysis, 2023
8.2. Company Profiles
8.2.1. Lonza
8.2.1.1. Company overview
8.2.1.2. Financial performance
8.2.1.3. Service benchmarking
8.2.1.4. Strategic initiatives
8.2.2. Catalent, Inc
8.2.2.1. Company overview
8.2.2.2. Financial performance
8.2.2.3. Service benchmarking
8.2.2.4. Strategic initiatives
8.2.3. Thermo Fisher Scientific Inc.
8.2.3.1. Company overview
8.2.3.2. Financial performance
8.2.3.3. Service benchmarking
8.2.3.4. Strategic initiatives
8.2.4. Cambrex Corporation
8.2.4.1. Company overview
8.2.4.2. Financial performance
8.2.4.3. Service benchmarking
8.2.4.4. Strategic initiatives
8.2.5. Bellen Chemistry
8.2.5.1. Company overview
8.2.5.2. Financial performance
8.2.5.3. Service benchmarking
8.2.5.4. Strategic initiatives
8.2.6. Siegfried Holding AG
8.2.6.1. Company overview
8.2.6.2. Financial performance
8.2.6.3. Service benchmarking
8.2.6.4. Strategic initiatives
8.2.7. Recipharm AB
8.2.7.1. Company overview
8.2.7.2. Financial performance
8.2.7.3. Service benchmarking
8.2.7.4. Strategic initiatives
8.2.8. Eurofins Scientific
8.2.8.1. Company overview
8.2.8.2. Financial performance
8.2.8.3. Service benchmarking
8.2.8.4. Strategic initiatives
8.2.9. Aurigene Pharmaceutical Services Ltd.
8.2.9.1. Company overview
8.2.9.2. Financial performance
8.2.9.3. Service benchmarking
8.2.9.4. Strategic initiatives
8.2.10. CordenPharma International
8.2.10.1. Company overview
8.2.10.2. Financial performance
8.2.10.3. Service benchmarking
8.2.10.4. Strategic initiatives





 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(バイオ薬物)の最新刊レポート


よくあるご質問


Grand View Research社はどのような調査会社ですか?


グランドビューリサーチ(Grand View Research)は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/07 10:27

155.63 円

167.26 円

203.27 円

ページTOPに戻る